Astrantus’s GSK GSK Stock Holding History

Astrantus’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-17,806	Closed	-$982K	–	225
2021 Q4	$982K	Buy	+17,806	New	+$926K	0.73%	40

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Astrantus's GSK Position: Q1 2022 in Review

Astrantus sold out of GSK (GSK) in Q1 2022, closing a stake of 17,806 shares — an estimated $982K sold.

Astrantus first reported a position in GSK in Q4 2021 and held it in 1 quarter. The position peaked at $982K in Q4 2021. 930 funds tracked by Wall St. Rank hold GSK as of Q1 2022.

Astrantus reported no remaining GSK position as of Q1 2022 after selling out during the quarter.
Astrantus sold 17,806 GSK shares in Q1 2022, an estimated $982K.
Astrantus first reported a position in GSK in Q4 2021 and held it in 1 quarter.
Astrantus's GSK position peaked at $982K in Q4 2021.
930 funds tracked by Wall St. Rank held GSK as of Q1 2022.

Based on Astrantus's 13F filing for Q1 2022, filed 11 May 2022.